Literature DB >> 1175143

Measurement of urinary CEA-like substance. An aid in management of patients with bladder carcinoma.

B Wahren, F Edsmyr, R Zimmerman.   

Abstract

Urine and serum samples from patients with bladder carcinomas were studied for the occurrence of and variations in CEA content before, during, and after radiation therapy. The concentration of CEA-like substances in urine increased with a more advanced clinical stage of the tumor, although there were large intercase variations. In serum, slightly increased values were noted only in advanced cases. During radiation therapy, high CEA values were found at around mid-course. This could be related to a breakdown of tumor tissue. Judging from data for urine from radiation-treated prostatic carcinomas without known tumors in the bladder, radiation alone was not responsible for the elevation of CEA. Urinary infections contributed to raised levels of CEA-like substances in some cases. At the end of successful radiation therapy (as verified by cystoscopy, cytology, and clinical examination), 25 patients had CEA values in the urine comparable to normal values (14 +/- 7 ng CEA/ml). The decrease was significant from the initial values to those after radiotherapy (p less than 0.01). Four patients whose tumors persisted had high values (68 +/- 46 ng CEA/ml). In patients who had previously received radiation treatment for bladder carcinomas, CEA values were high in 20 with recurrences (58 +/- 36 ng CEA/ml) while they were lower in 13 who were free of recurrence (14 +/- 6 ng CEA/ml). These findings indicate that urinary CEA determinations may be used in the immediate followup and management of patients treated for bladder carcinoma. It also appears to be of prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175143     DOI: 10.1002/1097-0142(197510)36:4<1490::aid-cncr2820360442>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Isolation of CEA-like material from urinary bladder carcinoma.

Authors:  R Zimmerman; S Hammarström
Journal:  Urol Res       Date:  1978

2.  Carcinoembryonic antigen in serum, urine and cells of patients with bladder carcinoma.

Authors:  B Wahren; F Edsmyr
Journal:  Urol Res       Date:  1978

3.  Immunohistochemical demonstration of tumor-associated antigens with the aid of monoclonal and polyclonal antisera in carcinoma of the bladder.

Authors:  J Steffens; W Friedmann; H Lobeck
Journal:  Urol Res       Date:  1985

4.  Tumour markers in urology: aids in cancer diagnosis and management.

Authors:  B Wahren
Journal:  Urol Res       Date:  1979-06-22

5.  Immunoperoxidase staining of carcinoembryonic antigen in urinary bladder cancer.

Authors:  D M Goldenberg; B Wahren
Journal:  Urol Res       Date:  1978

6.  Elevated serum levels of a biliary glycoprotein (BGP I) in patients with liver or biliary tract disease.

Authors:  T Svenberg; B Wahren; S Hammarström
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

7.  Quantitation and immunochemical characterization of carcinoembryonic antigen and glucose phosphate isomerase in blood and washings of patients with gastric and colonic diseases.

Authors:  D Munjal; P G Brady
Journal:  Am J Dig Dis       Date:  1978-01

8.  Possibilities for an extended classification of bladder cancer.

Authors:  B Wahren; B Nilsson; P L Esposti; F Edsmyr; V Holmberg
Journal:  Urol Res       Date:  1984

9.  Prediction of survival and recurrence in bladder carcinoma.

Authors:  B Nilsson; B Wahren; P L Esposti; F Edsmyr
Journal:  Urol Res       Date:  1982

Review 10.  Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?

Authors:  Nada Humayun-Zakaria; Douglas G Ward; Roland Arnold; Richard T Bryan
Journal:  Transl Androl Urol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.